AAS
VRCA icon

Ameritas Advisory Services’s Verrica Pharmaceuticals VRCA Stock Holding History

Ameritas Advisory Services’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30
Closed -$159 – 2920
2025
Q2 		$159 Buy
+30
New +$161 ﹤0.01% 2773

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Ameritas Advisory Services's VRCA Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 30 shares — an estimated $159 sold.

Ameritas Advisory Services first reported a position in VRCA in Q2 2025 and held it in 1 quarter. The position peaked at $159 in Q2 2025. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Ameritas Advisory Services reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 30 Verrica Pharmaceuticals shares in Q3 2025, an estimated $159.
  • Ameritas Advisory Services first reported a position in Verrica Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Ameritas Advisory Services's Verrica Pharmaceuticals position peaked at $159 in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.